Kintor Pharmaceutical Limited (KNTPF)

Market Cap	151.25M +90.7%
Revenue (ttm)	4.67M +553.6%
Net Income	-28.61M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	675
Open	0.2801
Previous Close	n/a
Day's Range	0.2801 - 0.2801
52-Week Range	0.2160 - 0.5708
Beta	-0.55
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Kintor Pharmaceutical

Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People’s Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is developing GT1708F (Hedgehog/SMO Inhibitor), an inhibit...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 123
• Stock Exchange: OTCMKTS
• Ticker Symbol: KNTPF

Financial Performance

In 2025, Kintor Pharmaceutical's revenue was 32.68 million, an increase of 553.64% compared to the previous year's 5.00 million. Losses were -200.11 million, 28.9% more than in 2024.

Financial numbers in CNY